KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
August 09 2022 - 7:30AM
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a
specialty pharmaceutical company focused on the discovery,
development and commercialization of novel treatments for rare
central nervous system (CNS), neurodegenerative and lysosomal
storage diseases, today announced the appointment of Nichol Ochsner
to the role of Vice President, Investor Relations and Corporate
Communications. In this newly created position, Ms. Ochsner will be
responsible for driving external awareness of KemPharm’s value
proposition, including ongoing relations with the Company’s
shareholders, covering analysts and prospective investors.
“We are very pleased to welcome Nichol to
KemPharm and look forward to benefitting from her more than 20
years’ experience developing investor relations and corporate
communications strategies in the biopharmaceutical industry,”
stated Travis Mickle, Ph.D., President and CEO of KemPharm. “With
the addition of arimoclomol, the ongoing advancement of our
clinical pipeline, led by KP1077, and the continued
commercialization of AZSTARYS®, KemPharm offers multiple
opportunities for growth that have appeal to a wide array of
stakeholders. Nichol possesses an extensive communications skillset
that is ideally suited to positioning such a multifaceted value
proposition and conveying our unique vision to the investment
community and other constituents.”
Prior to joining KemPharm, Ms. Ochsner served as
Executive Vice President of Investor Relations and Corporate
Communications with Statera Biopharma. Previously, Ms. Ochsner
served as Vice President, Investor Relations and Corporate
Communications at TherapeuticsMD. Prior to TherapeuticsMD, she was
Executive Director, Investor Relations and Corporate Communications
at Aralez Pharmaceutical, and, before that, served as Senior
Director, Investor Relations and Corporate Communications at
Auxilum until its acquisition by Endo International plc for $2.6
billion. Prior to Auxilum, she served as Director of Corporate
Communications at Medarex until the acquisition by Bristol Meyers
Squibb for $2.4 billion. She has also held positions at Kos
Pharmaceuticals, Genta, Enzon Pharmaceuticals and AXA Financial.
Ms. Ochchner holds a B.A. in Pre-Law from West Virginia
University.
“I am very excited to join KemPharm at this
important time in the Company’s growth and evolution,” stated Ms.
Ochsner. “KemPharm is rare among small biopharmaceutical companies
in that it possesses a deep and diverse clinical pipeline coupled
with revenue-generating pre-NDA and commercial-stage assets, along
with a strong balance sheet. This is a very compelling story, and
one that I look forward to showcasing across our continuum of
stakeholders.”
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery, development and commercialization of
novel treatments for rare central nervous system (CNS),
neurodegenerative and lysosomal storage diseases. KemPharm has a
diverse product portfolio, combining a clinical-stage development
pipeline with revenue-generating NDA-stage and commercial assets.
The pipeline includes arimoclomol, an orally-delivered,
first-in-class treatment for Niemann-Pick disease type C (NPC), and
KP1077, which the company is developing as a treatment for
idiopathic hypersomnia (IH), a rare neurological sleep disorder,
and narcolepsy. In addition, the U.S. Food and Drug Administration
(FDA) has approved AZSTARYS®, a once-daily treatment for ADHD in
patients aged six years and older containing KemPharm’s prodrug,
serdexmethylphenidate (SDX), which is being commercialized by
Corium, Inc. in the U.S., and APADAZ®, an immediate-release
combination product containing benzhydrocodone, KemPharm’s prodrug
of hydrocodone, and acetaminophen, which is being commercialized by
KVK-Tech, Inc. in the U.S. For more information on KemPharm and its
pipeline of product candidates visit www.kempharm.com or connect
with us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc. Jason Rando/Daniel
Kontoh-Boatengjrando@tiberend.com dboateng@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024